{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T01:40:48Z","timestamp":1782178848089,"version":"3.54.5"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T00:00:00Z","timestamp":1683849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T00:00:00Z","timestamp":1683849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s00277-023-05248-9","type":"journal-article","created":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T12:02:12Z","timestamp":1683892932000},"page":"2069-2075","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["N-Acetylcistein for thrombotic thrombocytopenic purpura: an observational case series study"],"prefix":"10.1007","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5145-7711","authenticated-orcid":false,"given":"Ignacio","family":"Espa\u00f1ol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Diego","family":"Leal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Blanquer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faustino","family":"Garc\u00eda-Candel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Heredia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaqu\u00edn","family":"G\u00f3mez-Espuch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Montserrat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Sacramento","family":"D\u00edaz-Carrasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 M.","family":"Moraleda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,12]]},"reference":[{"issue":"6855","key":"5248_CR1","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/35097008","volume":"413","author":"GG Levy","year":"2001","unstructured":"Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee BM et al (2001) Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 413(6855):488\u2013494. https:\/\/doi.org\/10.1038\/35097008","journal-title":"Nature"},{"issue":"10","key":"5248_CR2","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1111\/jth.13764","volume":"15","author":"M Saha","year":"2017","unstructured":"Saha M, McDaniel JK, Zheng XL (2017) Thrombotic thrombocytopenic purpura: pathogenesis, diagnosis and potential novel therapeutics. J Thromb Haemost 15(10):1889\u20131900. https:\/\/doi.org\/10.1111\/jth.13764","journal-title":"J Thromb Haemost"},{"key":"5248_CR3","doi-asserted-by":"publisher","first-page":"757192","DOI":"10.3389\/fimmu.2021.757192","volume":"12","author":"A Laghmouchi","year":"2021","unstructured":"Laghmouchi A, Gra\u00e7a NAG, Voorberg J (2021) Emerging concepts in immune thrombotic thrombocytopenic purpura. Front Immunol 12:757192. https:\/\/doi.org\/10.3389\/fimmu.2021.757192","journal-title":"Front Immunol"},{"issue":"6","key":"5248_CR4","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1080\/17474086.2019.1611423","volume":"12","author":"BS Joly","year":"2019","unstructured":"Joly BS, Coppo P, Veyradier A (2019) An update on pathogenesis and diagnosis of thrombotic thrombocytopenic purpura. Expert Rev Hematol 12(6):383\u2013395. https:\/\/doi.org\/10.1080\/17474086.2019.1611423","journal-title":"Expert Rev Hematol"},{"issue":"6","key":"5248_CR5","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/nejm199108083250604","volume":"325","author":"GA Rock","year":"1991","unstructured":"Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC et al (1991) Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 325(6):393\u2013397. https:\/\/doi.org\/10.1056\/nejm199108083250604","journal-title":"N Engl J Med"},{"key":"5248_CR6","doi-asserted-by":"publisher","unstructured":"Coppo P, Froissart A (2015) French Reference Center for Thrombotic Microangiopathies. Treatment of thrombotic thrombocytopenic purpura beyond therapeutic plasma exchange. Hematology Am Soc Hematol Educ Program:637\u2013643. https:\/\/doi.org\/10.1182\/asheducation-2015.1.637","DOI":"10.1182\/asheducation-2015.1.637"},{"issue":"21","key":"5248_CR7","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1182\/blood-2016-10-709857","volume":"129","author":"BS Joly","year":"2017","unstructured":"Joly BS, Coppo P, Veyradier A (2017) Thrombotic thrombocytopenic purpura. Blood 129(21):2836\u20132846. https:\/\/doi.org\/10.1182\/blood-2016-10-709857","journal-title":"Blood"},{"issue":"6","key":"5248_CR8","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1056\/nejm199108083250605","volume":"325","author":"WR Bell","year":"1991","unstructured":"Bell WR, Braine HG, Ness PM, Kickler TS (1991) Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. N Engl J Med 325(6):398\u2013403. https:\/\/doi.org\/10.1056\/nejm199108083250605","journal-title":"N Engl J Med"},{"issue":"3","key":"5248_CR9","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.tracli.2017.05.015","volume":"24","author":"P Coppo","year":"2017","unstructured":"Coppo P (2017) French Reference Center for Thrombotic Microangiopathies. Management of thrombotic thrombocytopenic purpura. Transfus Clin Biol 24(3):148\u2013153. https:\/\/doi.org\/10.1016\/j.tracli.2017.05.015","journal-title":"Transfus Clin Biol"},{"issue":"1","key":"5248_CR10","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1097\/ccm.0b013e31822e9d66","volume":"40","author":"A Froissart","year":"2012","unstructured":"Froissart A, Buffet M, Veyradier A, Poullin P, Prov\u00f4t F, Malot S et al (2012) Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center. Crit Care Med 40(1):104\u2013111. https:\/\/doi.org\/10.1097\/ccm.0b013e31822e9d66","journal-title":"Crit Care Med"},{"issue":"8","key":"5248_CR11","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1182\/bloodadvances.2020001834","volume":"5","author":"F Peyvandi","year":"2021","unstructured":"Peyvandi F, Cataland S, Scully M, Coppo P, Knoebl P, Kremer Hovinga JA et al (2021) Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis. Blood Adv 5(8):2137\u20132141. https:\/\/doi.org\/10.1182\/bloodadvances.2020001834","journal-title":"Blood Adv"},{"issue":"2","key":"5248_CR12","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/jth.12790","volume":"13","author":"Y Benhamou","year":"2015","unstructured":"Benhamou Y, Boelle P-Y, Baudin B, Ederhy S, Gras J, Galicier L et al (2015) Cardiac troponin-I on diagnosis predicts early death and refractoriness in acquired thrombotic thrombocytopenic purpura. Experience of the French Thrombotic Microangiopathies Reference Center. J Thromb Haemost 13(2):293\u2013302. https:\/\/doi.org\/10.1111\/jth.12790","journal-title":"J Thromb Haemost"},{"issue":"8","key":"5248_CR13","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.3324\/haematol.2011.049676","volume":"97","author":"Y Benhamou","year":"2012","unstructured":"Benhamou Y, Assi\u00e9 C, Boelle P-Y, Buffet M, Grillberger R, Malot S et al (2012) Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experience. Haematologica 97(8):1181\u20131186. https:\/\/doi.org\/10.3324\/haematol.2011.049676","journal-title":"Haematologica"},{"issue":"11","key":"5248_CR14","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1007\/s00277-016-2804-x","volume":"95","author":"AE Eskazan","year":"2016","unstructured":"Eskazan AE (2016) Bortezomib therapy in patients with relapsed\/refractory acquired thrombotic thrombocytopenic purpura. Ann Hematol 95(11):1751\u20131756. https:\/\/doi.org\/10.1007\/s00277-016-2804-x","journal-title":"Ann Hematol"},{"key":"5248_CR15","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1182\/asheducation-2018.1.539","volume":"1","author":"K Dane","year":"2018","unstructured":"Dane K, Chaturvedi S (2018) Beyond plasma exchange: novel therapies for thrombotic thrombocytopenic purpura. Hematology Am Soc Hematol Educ Program 1:539\u2013547. https:\/\/doi.org\/10.1182\/asheducation-2018.1.539","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"2","key":"5248_CR16","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1172\/jci41062","volume":"121","author":"J Chen","year":"2011","unstructured":"Chen J, Reheman A, Gushiken FC, Nolasco L, Fu X, Moake JL et al (2011) N-acetylcysteine reduces the size and activity of von Willebrand factor in human plasma and mice. J Clin Invest 121(2):593\u2013603. https:\/\/doi.org\/10.1172\/jci41062","journal-title":"J Clin Invest"},{"issue":"5","key":"5248_CR17","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1111\/trf.12440","volume":"54","author":"GW Li","year":"2014","unstructured":"Li GW, Rambally S, Kamboj J, Reilly S, Moake JL, Udden MM et al (2014) Treatment of refractory thrombotic thrombocytopenic purpura with N-acetylcysteine: a case report. Transfusion 54(5):1221\u20131224. https:\/\/doi.org\/10.1111\/trf.12440","journal-title":"Transfusion"},{"key":"5248_CR18","first-page":"21","volume":"24","author":"E Moschcowittz","year":"1924","unstructured":"Moschcowittz E (1924) Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease. Proc N Pathol Soc 24:21\u201324","journal-title":"Proc N Pathol Soc"},{"issue":"23","key":"5248_CR19","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1056\/nejm198212023072306","volume":"307","author":"JL Moake","year":"1982","unstructured":"Moake JL, Rudy CK, Troll JH, Weinstein MJ, Colannino NM, Azocar J et al (1982) Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 307(23):1432\u20131435. https:\/\/doi.org\/10.1056\/nejm198212023072306","journal-title":"N Engl J Med"},{"issue":"2","key":"5248_CR20","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1111\/bjh.18040","volume":"197","author":"NAG Gra\u00e7a","year":"2022","unstructured":"Gra\u00e7a NAG, Joly BS, Voorberg J, Vanhoorelbeke K, B\u00e9ranger N, Veyradier A et al (2022) TTP: From empiricism for an enigmatic disease to targeted molecular therapies. Br J Haematol 197(2):156\u2013170. https:\/\/doi.org\/10.1111\/bjh.18040","journal-title":"Br J Haematol"},{"issue":"S1","key":"5248_CR21","doi-asserted-by":"publisher","first-page":"37","DOI":"10.5045\/br.2022.2022005","volume":"57","author":"SH Bae","year":"2022","unstructured":"Bae SH, Kim SH, Bang SM (2022) Recent advances in the management of immune-mediated thrombotic thrombocytopenic purpura. Blood Res 57(S1):37\u201343. https:\/\/doi.org\/10.5045\/br.2022.2022005","journal-title":"Blood Res"},{"key":"5248_CR22","doi-asserted-by":"publisher","first-page":"100945","DOI":"10.1016\/j.blre.2022.100945","volume":"55","author":"M Subhan","year":"2022","unstructured":"Subhan M, Scully M (2022) Advances in the management of TTP. Blood Rev 55:100945. https:\/\/doi.org\/10.1016\/j.blre.2022.100945","journal-title":"Blood Rev"},{"issue":"8","key":"5248_CR23","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1182\/blood-2016-09-738856","volume":"129","author":"C Tersteeg","year":"2017","unstructured":"Tersteeg C, Roodt J, Van Rensburg WJ, Dekimpe C, Vandeputte N, Pareyn I et al (2017) N-acetylcysteine in preclinical mouse and baboon models of thrombotic thrombocytopenic purpura. Blood 129(8):1030\u20131038. https:\/\/doi.org\/10.1182\/blood-2016-09-738856","journal-title":"Blood"},{"issue":"5","key":"5248_CR24","doi-asserted-by":"publisher","first-page":"e1277","DOI":"10.1097\/mjt.0000000000000386","volume":"23","author":"G Cabanillas","year":"2016","unstructured":"Cabanillas G, Popescu-Martinez A (2016) N-Acetylcysteine for relapsing thrombotic thrombocytopenic purpura: more evidence of a promising drug. Am J Ther 23(5):e1277\u2013e1279. https:\/\/doi.org\/10.1097\/mjt.0000000000000386","journal-title":"Am J Ther"},{"issue":"4","key":"5248_CR25","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1007\/s11239-015-1259-6","volume":"41","author":"AH-KS Rottenstreich","year":"2016","unstructured":"Rottenstreich AH-KS (2016) The role of N-acetylcysteine in the treatment of thrombotic thrombocytopenic purpura. J Thromb Thrombolysis 41(4):678\u2013683. https:\/\/doi.org\/10.1007\/s11239-015-1259-6","journal-title":"J Thromb Thrombolysis"},{"issue":"1","key":"5248_CR26","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1056\/nejmc1213206","volume":"368","author":"J Shortt","year":"2013","unstructured":"Shortt J, Oh DH, Opat SS (2013) ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura. N Engl J Med 368(1):90\u201392. https:\/\/doi.org\/10.1056\/nejmc1213206","journal-title":"N Engl J Med"},{"issue":"9","key":"5248_CR27","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.1111\/trf.12787","volume":"54","author":"J Shortt","year":"2014","unstructured":"Shortt J, Opat SS, Wood EM (2014) N-Acetylcysteine for thrombotic thrombocytopenic purpura: is a von Willebrand factor-inhibitory dose feasible in vivo? Transfusion 54(9):2362\u20132363. https:\/\/doi.org\/10.1111\/trf.12787","journal-title":"Transfusion"},{"key":"5248_CR28","doi-asserted-by":"publisher","unstructured":"Acedillo RR, Govind M, Kashgary A, Clark WF (2016) Treatment of severe, refractory and rapidly evolving thrombotic thrombocytopenic purpura. BMJ Case Rep 2016. https:\/\/doi.org\/10.1136\/bcr-2016-215491","DOI":"10.1136\/bcr-2016-215491"},{"issue":"6","key":"5248_CR29","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1111\/j.1365-2141.2012.09084.x","volume":"157","author":"J Chapin","year":"2012","unstructured":"Chapin J, Weksler B, Magro C, Laurence J (2012) Eculizumab in the treatment of refractory idiopathic thrombotic thrombocytopenic purpura. Br J Haematol 157(6):772\u2013774. https:\/\/doi.org\/10.1111\/j.1365-2141.2012.09084.x","journal-title":"Br J Haematol"},{"key":"5248_CR30","first-page":"01","volume":"4","author":"I Espa\u00f1ol","year":"2019","unstructured":"Espa\u00f1ol I, Leal JD, G\u00f3mez J, Montserrat J, Garc\u00eda-Candel F, Moraleda JM et al (2019) N-Acetylcysteine for refractory acquired thrombotic thrombocytopenic purpura: new dosage approaches. Clin Case Rep Rese & Trials 4:01\u201307","journal-title":"Clin Case Rep Rese & Trials"},{"issue":"4","key":"5248_CR31","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1177\/0036933018775240","volume":"63","author":"S Demircioglu","year":"2018","unstructured":"Demircioglu S, Ekinci O, Dog\u00e2n A, Demir C (2018) Relapsed\/refractory thrombotic thrombocytopenic purpura treated with N-acetylcysteine: a case report. Scott Med J 63(4):122\u2013124. https:\/\/doi.org\/10.1177\/0036933018775240","journal-title":"Scott Med J"},{"issue":"8","key":"5248_CR32","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1182\/blood-2009-09-243790","volume":"115","author":"JA Kremer Hovinga","year":"2010","unstructured":"Kremer Hovinga JA, Vesely SK, Terrell DR, L\u00e4mmle B, George JN (2010) Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood 115(8):1500\u20131511; quiz 1662. https:\/\/doi.org\/10.1182\/blood-2009-09-243790","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05248-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05248-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05248-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T15:38:14Z","timestamp":1744213094000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05248-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,12]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["5248"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05248-9","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,12]]},"assertion":[{"value":"28 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}